Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies.

The hereditary type IV collagen disease Alport syndrome (AS) always leads to end-stage renal failure. Yesterday, for the past 90 years, this course was described as 'inevitable'. Today, RAAS blockade has changed the 'inevitable' course to a treatable disease. Tomorrow, researchers hope to erase the 'always' from 'always leads to renal failure' in the textbooks. This review elucidates therapeutic targets that evolve from research: (i) kidney embryogenesis and pathogenesis; (ii) phenotype-genotype correlation and the role of collagen receptors and podocytes; (iii) the malfunctioning Alport-GBM; (iv) tubulointerstitial fibrosis; (v) the role of proteinuria in pathogenesis and prognosis; and (vi) secondary events such as infections, hyperparathyroidism and hypercholesterolaemia. Therefore, moderate lifestyle, therapy of bacterial infections, Paricalcitol in adult patients with hyperparathyroidism and HMG-CoA-reductase inhibitors in adult patients with dyslipoproteinemia might contribute to a slower progression of AS and less cardiovascular events. In the future, upcoming treatments including stem cells, chaperon therapy, collagen receptor blockade and anti-microRNA therapy will expand our perspective in protecting the kidneys of Alport patients from further damage. This perspective on current and future therapies is naturally limited by our personal focus in research, but aims to motivate young scientists and clinicians to find a multimodal cure for AS.

[1]  R. Girgert,et al.  Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  K. Nakanishi,et al.  Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. , 2014, Kidney international.

[3]  J. Miner,et al.  Feasibility of repairing glomerular basement membrane defects in Alport syndrome. , 2014, Journal of the American Society of Nephrology : JASN.

[4]  H. Dweep,et al.  Evidence for activation of the unfolded protein response in collagen IV nephropathies. , 2014, Journal of the American Society of Nephrology : JASN.

[5]  K. Kadler,et al.  Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke , 2013, Human molecular genetics.

[6]  M. Takasato,et al.  Recreating kidney progenitors from pluripotent cells , 2014, Pediatric Nephrology.

[7]  K. Lemley,et al.  A Novel Source of Cultured Podocytes , 2013, PloS one.

[8]  M. Takasato,et al.  Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. , 2013, Journal of the American Society of Nephrology : JASN.

[9]  J. Papillon,et al.  Nephrin missense mutations: induction of endoplasmic reticulum stress and cell surface rescue by reduction in chaperone interactions , 2013, Physiological reports.

[10]  Y. Kikkawa,et al.  Laminin β2 gene missense mutation produces endoplasmic reticulum stress in podocytes. , 2013, Journal of the American Society of Nephrology : JASN.

[11]  M. Walther,et al.  Diagnosis of Alport syndrome—search for proteomic biomarkers in body fluids , 2013, Pediatric Nephrology.

[12]  D. Rubel,et al.  Alport syndrome—insights from basic and clinical research , 2013, Nature Reviews Nephrology.

[13]  Jie Ding,et al.  Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. , 2013, Journal of the American Society of Nephrology : JASN.

[14]  Chad A. Cowan,et al.  Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells , 2013, Nature Communications.

[15]  C. Licht,et al.  An update on the pathomechanisms and future therapies of Alport syndrome , 2013, Pediatric Nephrology.

[16]  H. Anders,et al.  Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non‐inflammatory glomerular injury , 2012, The Journal of pathology.

[17]  F. Dekker,et al.  Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[18]  P. Kerr,et al.  The Directed Differentiation of Human iPS Cells into Kidney Podocytes , 2012, PloS one.

[19]  B. Kasinath,et al.  TGFβ-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion , 2012, PloS one.

[20]  M. Burke,et al.  Atypical fractures associated with bisphosphonate use post‐renal transplantation , 2012, Nephrology.

[21]  D. Warburton,et al.  Injection of amniotic fluid stem cells delays progression of renal fibrosis. , 2012, Journal of the American Society of Nephrology : JASN.

[22]  Jie Ding,et al.  Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative , 2012, Pediatric Nephrology.

[23]  T. Friede,et al.  Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. , 2012, Kidney international.

[24]  Aaron N. Chang,et al.  MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways , 2012, Science Translational Medicine.

[25]  S. Ricardo,et al.  Mesenchymal stem cells in kidney inflammation and repair , 2012, Nephrology.

[26]  Stefano Da Sacco,et al.  Regenerative medicine of the kidney. , 2011, Advanced drug delivery reviews.

[27]  H. Anders,et al.  Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. , 2011, Kidney international.

[28]  M. Kretzler,et al.  Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. , 2010, Matrix biology : journal of the International Society for Matrix Biology.

[29]  Timothy M. Williams,et al.  Macrophages in renal development, injury, and repair. , 2010, Seminars in nephrology.

[30]  J. Folkman,et al.  Stem cell therapies benefit Alport syndrome. , 2009, Journal of the American Society of Nephrology : JASN.

[31]  P. S. St. John,et al.  Cellular origins of type IV collagen networks in developing glomeruli. , 2009, Journal of the American Society of Nephrology : JASN.

[32]  Clair Baldock,et al.  Collagens at a glance , 2007, Journal of Cell Science.

[33]  A. Perkins,et al.  In vitro differentiation of murine embryonic stem cells toward a renal lineage. , 2007, Differentiation; research in biological diversity.

[34]  S. Segerer,et al.  Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  R. Poulsom,et al.  Bone Marrow‐Derived Cells Contribute to Podocyte Regeneration and Amelioration of Renal Disease in a Mouse Model of Alport Syndrome , 2006, Stem cells.

[36]  R. Kalluri,et al.  Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Kramer,et al.  Cells differentiated from mouse embryonic stem cells via embryoid bodies express renal marker molecules. , 2006, Differentiation; research in biological diversity.

[38]  Takahiko Kobayashi,et al.  Wnt4-transformed mouse embryonic stem cells differentiate into renal tubular cells. , 2005, Biochemical and biophysical research communications.

[39]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[40]  S. Sasaki,et al.  Intracellular mislocalization of mutant podocin and correction by chemical chaperones , 2003, Histochemistry and Cell Biology.

[41]  P. S. St. John,et al.  Laminin-1 reexpression in Alport mouse glomerular basement membranes1 , 2003 .

[42]  E. Schulze-Lohoff,et al.  Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. , 2003, Kidney international.

[43]  P. Zeitlin,et al.  Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. , 2002, Advanced drug delivery reviews.

[44]  O. Gross,et al.  Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[45]  R. Kalluri,et al.  Integrin α1β1 and Transforming Growth Factor-β1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy , 2000 .

[46]  Y. Sado,et al.  Type IV Collagen of the Glomerular Basement Membrane , 2000, The Journal of Biological Chemistry.

[47]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[48]  R. Kalluri,et al.  Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. , 2000, The American journal of pathology.

[49]  R. Kalluri,et al.  Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. , 1997, The Journal of clinical investigation.

[50]  J. Engel,et al.  A substitution of cysteine for glycine 748 of the alpha 1 chain produces a kink at this site in the procollagen I molecule and an altered N-proteinase cleavage site over 225 nm away. , 1988, The Journal of biological chemistry.

[51]  Alport Ac.  HEREDITARY FAMILIAL CONGENITAL HAEMORRHAGIC NEPHRITIS , 1927 .